Indoco Remedies Limited — Investor Meet, 28-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Indoco Remedies reported Q1 FY26 consolidated net revenues of Rs. 429.1 Cr and standalone net revenues of Rs. 383.8 Cr, showing Q-o-Q growth. Consolidated EBITDA turned positive at 4.1%. The OTC business surged over 46% Q-o-Q, hitting Rs. 31.6 Cr. Solid oral exports increased over 26%. US FDA allowed manufacturing on two lines at Goa Plant-2, with European approval for sterile products. Management expects to invite US FDA for audit from September. Net debt stands at Rs. 951 Cr. The company is focused on cost containment and sequential EBITDA improvement, aiming for 11-13% levels. Sentiment is cautiously optimistic.